MedPharm || طبصيدلة

Regarding evaluation of the therapeutic outcomes, hormonal replacement therapy as non-oral estrogen (Transdermal, intranasal, and vaginal products), usually preferred in some cases to get the benefit of all the following, EXCEPT: a- less likely to increase C-reactive protein levels b- less likely to decrease sex hormone-binding globulin c- Avoid first-pass metabolism and result in more physiologic estradiol:estrone ratio d- Lower risk for deep vein thrombosis, stroke, and myocardial infarction e- less likely to increase blood pressure

Q.E is 56 years old female presented to the gynecologist with hot flushes, and night sweat. She had her last menses 2 years ago. The patient had a history of breast cancer which was successfully cured 10 years ago. Which one of the following medications could be started to alleviate Q.E's vasomotor symptoms? a- Estrogen replacement b- Progestin containing HRT c- Estrogen vaginal cream d- Venlafaxine e- Non-estrogen vaginal cream

Jane is a 48-year-old woman who is experiencing severe hot flashes and night sweats. She has a family history of breast cancer, but has no personal history of breast cancer or cardiovascular disease. Which medication may be a potential option for relieving Jane's hot flashes and night sweats, given her family history of breast cancer? a- Calcium and Vitamin D3 supplementation b- Hormone replacement therapy c- gabapentin d- corticosteroids e- none of the above